Clinical Trials Logo

Clinical Trial Summary

The objective of this study is to apply a validated machine-learning based model (SHIELD-RT, NCT04277650) to a cohort of patients undergoing systemic therapy as outpatient cancer treatment to generate an automatic system for the prediction of unplanned hospital admission rates and emergency department encounters.


Clinical Trial Description

A previously described machine learning (ML)-based model accurately predicted ED visits or hospitalizations for cancer patients undergoing radiation therapy or chemoradiation. An IRB approved prospective randomized trial, SHIELD-RT (NCT04277650) found that preemptive intervention for patients undergoing radiation and chemoradiation based on the ML model's risk stratification decreased the relative risk of acute care visits by 50%, showing that ML-guided escalation of care improved personalized supportive care and treatment compliance while decreasing healthcare costs. The objective of this study is to apply this validated ML based model to a cohort of patients undergoing systemic therapy as outpatient cancer treatment to generate an automatic system for the prediction of unplanned hospital admission rates and emergency department encounters. Once validated, this study will add to the previously published body of evidence supporting a randomized trial evaluating the ML algorithm's ability to assign intervention for patients receiving systemic therapy at highest risk for acute care encounters. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05122247
Study type Observational
Source Duke University
Contact Joan Cahill, BNS RN OCN CCRP
Phone (919) 668-5211
Email [email protected]
Status Not yet recruiting
Phase
Start date November 2021
Completion date July 2022

See also
  Status Clinical Trial Phase
Completed NCT04277650 - System for High-Intensity Evaluation During Radiotherapy N/A
Not yet recruiting NCT04965532 - Residual Neuromuscular Block of Rocuronium in Chemotherapy Patients Under Sevoflurane Anesthesia N/A
Active, not recruiting NCT04843410 - EFFECT OF EXERCISE IN THE MANAGEMENT OF CHEMOTHERAPY-RELATED PERIPHERAL NEUROPATHY N/A
Enrolling by invitation NCT04027478 - Can Fasting Decrease the Side Effects of Chemotherapy? N/A
Recruiting NCT04607668 - Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC): Phase 3
Completed NCT02996201 - Electronic Patient Reporting of Side Effects to Chemotherapy: A Cluster Randomized Controlled Trial N/A
Completed NCT00292526 - Prevention of Chemotherapy-induced Cardiotoxicity in High-risk Patients Phase 4
Not yet recruiting NCT05137860 - Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD Phase 4
Completed NCT04663178 - Foot Bath and Chemotherapy Induced Fatigue N/A
Suspended NCT03191461 - Myocardial Perfusion and Fibrosis in Cancer Survivors
Recruiting NCT04799080 - Chemotherapy-induced Peripheral Neuropathy (CIPN) on Motor and Sensory Function
Recruiting NCT04694794 - Diminish Chemotherapy Related Side Effects Through Patient Education N/A
Recruiting NCT04754672 - Aerobic Fitness or Muscle Mass Training to Improve Colorectal Cancer Outcome N/A
Recruiting NCT04319601 - Rituximab Combined With Chidamide and Lenalidomide for r/r AITL N/A
Completed NCT03908528 - Alpha-Lipoic Acid in Breast Cancer Patients N/A
Recruiting NCT04988971 - The Efficacy and Safety of a Compound Glutamine Capsule in the Prevention of Chemotherapy-induced Mucositis Phase 3
Recruiting NCT05092113 - The Efficacy and Safety of a Compound Glutamine Capsule in the Primary Prevention of Chemotherapy-induced Mucositis Phase 3
Not yet recruiting NCT04495387 - Improving Food Pleasure and Intake of Oncology Patients Receiving Chemotherapy
Recruiting NCT03039062 - Serum miR-122 as a Real-time Detection Biomarker of Drug-induced Liver Injury by Chemotherapy N/A
Not yet recruiting NCT03566394 - Prophylactic Gabapentin for Taxane-Induced Arthralgia and Myalgia Syndrome in Breast Cancer Patients Undergoing Adjuvant Chemotherapy Phase 2/Phase 3